Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Conditions
Keywords
WTX-330, Cancer, Immunotherapy, Interleukin-12, IL-12, Checkpoint inhibitor resistance
Brief summary
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
Detailed description
This is a first-in-human, Phase 1, open-label, multicenter study to evaluate the safety, tolerability and preliminary efficacy of WTX-330, a conditionally-activated IL-12 prodrug, when administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma. Dose escalation will be conducted in patients with advanced and/or metastatic solid tumors who are refractory to all standard of care therapies. Dose expansion will be conducted in two arms: Arm A will enroll patients with indications for which a checkpoint inhibitor (CPI) is indicated/approved who demonstrate primary or secondary resistance to an anti-PD(L)1 treatment regimen, and Arm B will enroll patients with tumor types for which CPI therapy is not indicated/approved.
Interventions
DRUGWTX-330
Investigation Product
Sponsors
Werewolf Therapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years. 2. Dose Escalation: A diagnosis of a relapsed/refractory advanced or metastatic solid tumor for which the patient has progressed on or is intolerant of standard therapy, or for whom no standard therapy with proven benefit exists. 3. Dose Expansion: A diagnosis of a relapsed/refractory advanced or metastatic malignancy for which the patient has progressed on or is intolerant of standard therapy, or for whom no standard therapy with proven benefit exists. For Arm A, patients must have a tumor type for which a CPI is indicated/approved and demonstrate primary or secondary resistance to a standard of care anti-PD(L)1-based treatment regimen. For Arm B, patients must have a solid tumor type for which a CPI is not indicated/approved or non-Hodgkin lymphoma. 4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 5. At least one measurable lesion per RECIST 1.1 or an evaluable lesion per Lugano classification (for lymphoma). 6. Agrees to undergo a pre-treatment and on-treatment biopsy of a primary or metastatic solid tumor or lymphoma lesion. 7. HIV-infected patients must be on antiretroviral therapy and have well-controlled disease. 8. Adequate organ and bone marrow function. 9. Willingness of men and women of reproductive potential to use highly effective birth control for the duration of treatment and for 4 months following the last dose of study drug. 10. Additional criteria may apply.
Exclusion criteria
1. A history of another active malignancy (i.e., a second cancer) within the previous 2 years, except for localized cancers that are not related to the current cancer being treated, are considered cured, and, in the opinion of the Investigator, present a low risk of recurrence. These exceptions include but are not limited to basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast. 2. Received prior treatment with IL-12, including by intratumoral injection. 3. Patients with primary CNS malignancies. 4. Presence of CNS metastases that are symptomatic and/or require local CNS directed therapy (such as XRT or surgery) or increasing doses of corticosteroids within 2 weeks prior to the first dose of study drug. Patients with treated brain metastases should be neurologically stable and receiving ≤ 10 mg per day of prednisone or equivalent prior to study entry. 5. Significant cardiovascular disease. 6. Significant electrocardiogram (ECG) abnormalities 7. Active autoimmune disease requiring systemic treatment in the past 2 years. 8. Diagnosis of immunodeficiency, on immunosuppressive therapy, or receiving chronic systemic or enteric steroid therapy (dose \> 10 mg/day of prednisone or equivalent). 9. Prior receipt of an allogeneic stem cell transplant or allogeneic CAR-T cell therapy. 10. Major surgery (excluding placement of vascular access) within 2 weeks prior to the first dose of study drug. 11. Investigational agent or anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, anticancer Chinese medicine, or anticancer herbal remedy) within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug. 12. Radiotherapy within 2 weeks of the start of study treatment. A 1-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease. 13. Any unresolved toxicities from prior therapy greater than NCI-CTCAE version 5.0 Grade 1 at the time of starting study drug with the exception of alopecia and Grade 2 platinum therapy-related neuropathy. 14. Use of sensitive substrates of major CYP450 isozymes. 15. Any illness, medical condition, organ system dysfunction, or social situation (including mental illness or substance abuse), that may interfere with a patient's ability to sign the ICF, adversely affect the patient's ability to cooperate and participate in the study, or compromise interpretation of study results. 16. Received a live vaccine within 30 days of the first dose of study drug. 17. Active, uncontrolled systemic bacterial, viral, or fungal infection. 18. HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease. 19. Active infection with hepatitis B as determined by hepatitis B surface antigen and hepatitis B core antibody, or hepatitis B virus deoxyribonucleic acid (DNA) by quantitative polymerase chain reaction (qPCR) testing. 20. Active infection with hepatitis C as determined by hepatitis C virus (HCV) antibody or HCV RNA by qPCR testing. 21. Pregnant or lactating. 22. History of hypersensitivity to any of the study drug components. 23. Additional criteria may apply
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Dose Limiting Toxicities (DLTs) | 4 weeks | A DLT is defined as an AE or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle of treatment with WTX-330 and meets any of the criteria included in the protocol |
| Incidence of Treatment Emergent Adverse Events | 24 months | AEs were graded and documented in accordance with NCI-CTCAE version 5.0 |
| Incidence of Changes in Clinical Laboratory Abnormalities | 24 months | Change from baseline is provided as baseline grade or normal/low/high and worst post-baseline grade. |
| Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas) | 24 months | RECIST = Response Evaluation Criteria in Solid Tumors |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Concentrations of WTX-330 Cycle 2 - C Max | 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2 | PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2 |
| Plasma Concentrations of WTX-330 Cycle 2 - Time of Maximum Concentration Observation | 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2 | PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2 |
| Plasma Concentrations of WTX-330 Cycle 2 - Half Life | 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2 | PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2 |
| Plasma Concentrations of WTX-330 Cycle 2 - AUC | 14 days | PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose. |
| Plasma Concentrations of IL-12 Cycle 1 - C Max | 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1 | PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1 |
| Plasma Concentrations of IL-12 Cycle 1 - Time of Maximum Concentration Observation | 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1 | PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1 |
| Plasma Concentrations of WTX-330 Cycle 1 - C Max | 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1 | PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1 |
| Plasma Concentrations of IL-12 Cycle 1 - AUC | 14 days | PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose. |
| Plasma Concentrations of IL-12 Cycle 2 - C Max | 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2 | PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2 |
| Plasma Concentrations of IL-12 Cycle 2 - Time of Maximum Concentration Observation | 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2 | PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2 |
| Plasma Concentrations of IL-12 Cycle 2 - Half Life | 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2 | PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2 |
| Plasma Concentrations of IL-12 Cycle 2 - AUC | 14 days | PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose. |
| Antidrug Antibody (ADA) Occurrence | 24 months | ADA were measured at Baseline and Post Baseline. Positive post baseline applies if at least one post-baseline value was positive. |
| Plasma Concentrations of IL-12 Cycle 1 - Half Life | 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1 | PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1 |
| Plasma Concentrations of WTX-330 Cycle 1 - Time of Maximum Concentration Observation | 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1 | PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1 |
| Plasma Concentrations of WTX-330 Cycle 1 - Half Life | 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1 | PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1 |
| Plasma Concentrations of WTX-330 Cycle 1 - AUC | 14 days | PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose. |
Countries
United States
Participant flow
Recruitment details
Participants were recruited based on their oncological history at 9 clinical research sites in the United States.
Pre-assignment details
36 potential participants underwent screening, 11 were screened out, and 25 were included in the trial.
Participants by arm
| Arm | Count |
|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg Patients with relapsed/refractory advanced or metastatic solid tumors received a dose of 0.016 mg/kg on Days 1 and 15 (i.e., every 2 weeks, Q2W) of 28-day treatment cycle | 3 |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg WTX-330 dose expansion in patients with tumor types for which a CPI is indicated/approved who demonstrate primary or secondary resistance to an anti-PD(L)1-based regimen | 5 |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg WTX-330 dose expansion in patients with tumor types for which a CPI is not indicated/ approved | 9 |
| WTX-330 Dose Escalation - 0.024 mg/kg Patients with relapsed/refractory advanced or metastatic solid tumors received a dose of 0.024 mg/kg on Days 1 and 15 (i.e., every 2 weeks, Q2W) of 28-day treatment cycle | 3 |
| WTX-330 Dose Escalation - 0.032 mg/kg Patients with relapsed/refractory advanced or metastatic solid tumors received a dose of 0.032 mg/kg on Days 1 and 15 (i.e., every 2 weeks, Q2W) of 28-day treatment cycle | 5 |
| Total | 25 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Death | 0 | 0 | 0 | 3 | 4 |
| Overall Study | Lost to Follow-up | 0 | 0 | 0 | 0 | 1 |
| Overall Study | Other | 0 | 0 | 0 | 2 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 1 | 3 | 0 | 1 |
Baseline characteristics
| Characteristic | Total | WTX-330 Dose Escalation - 0.032 mg/kg | WTX-330 Dose Escalation - 0.024 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B); 0.024 mg/kg | WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A); 0.024 mg/kg | WTX-330 Dose Escalation - 0.016 mg/kg |
|---|---|---|---|---|---|---|
| Age, Continuous | 64.4 years STANDARD_DEVIATION 9.44 | 61.8 years STANDARD_DEVIATION 10.13 | 65.00 years STANDARD_DEVIATION 11 | 68.2 years STANDARD_DEVIATION 7.9 | 60.6 years STANDARD_DEVIATION 11.55 | 63.3 years STANDARD_DEVIATION 10.26 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 22 Participants | 5 Participants | 2 Participants | 9 Participants | 5 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 21 Participants | 4 Participants | 3 Participants | 8 Participants | 5 Participants | 1 Participants |
| Sex: Female, Male Female | 12 Participants | 1 Participants | 2 Participants | 5 Participants | 2 Participants | 2 Participants |
| Sex: Female, Male Male | 13 Participants | 4 Participants | 1 Participants | 4 Participants | 3 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 3 | 0 / 5 | 3 / 5 | 5 / 9 |
| other Total, other adverse events | 3 / 3 | 3 / 3 | 5 / 5 | 5 / 5 | 9 / 9 |
| serious Total, serious adverse events | 0 / 3 | 1 / 3 | 2 / 5 | 3 / 5 | 8 / 9 |
Outcome results
Primary
Incidence of Changes in Clinical Laboratory Abnormalities
Change from baseline is provided as baseline grade or normal/low/high and worst post-baseline grade.
Time frame: 24 months
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 2 | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 1 | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 1 | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 3 | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 1 | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 1 | 3 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 1 | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 1 | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 1 | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 1 | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 2 | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 1 | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 1 | 3 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 1 | 3 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 1 | 3 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 3 | 3 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 1 | 3 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 2 | 2 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 1 | 2 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 3 | 2 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 0 | 4 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 1 | 2 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Missing | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 1 | 3 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 3 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Low - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 2 | 4 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 1 | 3 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 1 | 2 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 2 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 0 | 4 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Missing | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 1 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Missing | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 1 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 2 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 0 | 4 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 0 | 4 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 0 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 2 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Low - Grade 0 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 0 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 0 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 0 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 1 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 2 | 4 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 3 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 1 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 1 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 1 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 1 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 2 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 2 | 4 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 0 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 0 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 2 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 0 - Grade 0 | 8 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 2 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 1 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 1 | 4 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Normal - Grade 0 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 1 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | High - Grade 0 | 4 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Normal - Grade 0 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 0 - Grade 0 | 9 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 0 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 2 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 4 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 3 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 0 | 9 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 0 | 9 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 0 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 1 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 0 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 3 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 0 - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 2 - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alkaline phosphatase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count decreased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 0 | 4 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 1 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 2 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Normal - Grade 1 | 4 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 1 - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Alanine aminotransferase increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Missing | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | INR increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 1 | 6 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hemoglobin increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 0 | 8 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Lymphocyte count increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 1 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Anemia | Grade 0 - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 1 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | GGT increased | Grade 0 - Grade 0 | 6 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Activated partial thromboplastin time prolonged | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyperkalemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 0 | 9 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 1 - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 2 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Creatinine increased | Grade 0 - Grade 0 | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 0 | 6 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 0 - Grade 4 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 2 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypokalemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 3 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 0 | 7 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 1 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 2 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoglycemia | Grade 1 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | White blood cell decreased | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 3 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypoalbuminemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | High - Grade 1 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Platelet count decreased | Grade 4 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 1 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Normal - Grade 0 | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Grade 0 - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypomagnesemia | High - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | High - Grade 3 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 0 | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Blood bilirubin increased | Low - Grade 0 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Missing | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypernatremia | Normal - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 2 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 3 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 3 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 2 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hypermagnesemia | Normal - Grade 1 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 4 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 1 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Hyponatremia | Grade 0 - Grade 4 | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Changes in Clinical Laboratory Abnormalities | Aspartate aminotransferase increased | Grade 0 - Grade 4 | 0 Participants |
Primary
Incidence of Dose Limiting Toxicities (DLTs)
A DLT is defined as an AE or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle of treatment with WTX-330 and meets any of the criteria included in the protocol
Time frame: 4 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Dose Limiting Toxicities (DLTs) | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Dose Limiting Toxicities (DLTs) | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Dose Limiting Toxicities (DLTs) | 1 Participants |
Primary
Incidence of Treatment Emergent Adverse Events
AEs were graded and documented in accordance with NCI-CTCAE version 5.0
Time frame: 24 months
Population: Safety Analysis Set included all participants
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Treatment Emergent Adverse Events | TEAE | 3 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Treatment Emergent Adverse Events | TEAEs Related to WTX-330 | 3 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Treatment Emergent Adverse Events | Grade 3 or Higher TEAEs | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Treatment Emergent Adverse Events | Grade 3 or Higher TEAEs Related to WTX-330 | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Treatment Emergent Adverse Events | Serious TEAEs | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Incidence of Treatment Emergent Adverse Events | Serious TEAEs Related to WTX-330 | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Treatment Emergent Adverse Events | Serious TEAEs | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Treatment Emergent Adverse Events | Serious TEAEs Related to WTX-330 | 1 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Treatment Emergent Adverse Events | TEAE | 3 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Treatment Emergent Adverse Events | Grade 3 or Higher TEAEs | 3 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Treatment Emergent Adverse Events | Grade 3 or Higher TEAEs Related to WTX-330 | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Incidence of Treatment Emergent Adverse Events | TEAEs Related to WTX-330 | 3 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Treatment Emergent Adverse Events | Grade 3 or Higher TEAEs Related to WTX-330 | 4 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Treatment Emergent Adverse Events | Serious TEAEs | 2 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Treatment Emergent Adverse Events | TEAE | 5 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Treatment Emergent Adverse Events | Grade 3 or Higher TEAEs | 4 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Treatment Emergent Adverse Events | TEAEs Related to WTX-330 | 5 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Incidence of Treatment Emergent Adverse Events | Serious TEAEs Related to WTX-330 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Treatment Emergent Adverse Events | Grade 3 or Higher TEAEs Related to WTX-330 | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Treatment Emergent Adverse Events | TEAEs Related to WTX-330 | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Treatment Emergent Adverse Events | Grade 3 or Higher TEAEs | 4 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Treatment Emergent Adverse Events | Serious TEAEs Related to WTX-330 | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Treatment Emergent Adverse Events | Serious TEAEs | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Incidence of Treatment Emergent Adverse Events | TEAE | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Treatment Emergent Adverse Events | Serious TEAEs | 8 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Treatment Emergent Adverse Events | Grade 3 or Higher TEAEs | 8 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Treatment Emergent Adverse Events | TEAEs Related to WTX-330 | 9 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Treatment Emergent Adverse Events | Serious TEAEs Related to WTX-330 | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Treatment Emergent Adverse Events | Grade 3 or Higher TEAEs Related to WTX-330 | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Incidence of Treatment Emergent Adverse Events | TEAE | 9 Participants |
Primary
Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas)
RECIST = Response Evaluation Criteria in Solid Tumors
Time frame: 24 months
Population: The overall number of participants analyzed is lower than the overall study population, as the efficacy evaluable analysis set does not include all enrolled participants
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas) | ORR by RECIST | 0 Percent of participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas) | immune ORR by iRECIST | 0 Percent of participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas) | ORR by RECIST | 33.3 Percent of participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas) | immune ORR by iRECIST | 33.3 Percent of participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas) | ORR by RECIST | 0 Percent of participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas) | immune ORR by iRECIST | 0 Percent of participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas) | immune ORR by iRECIST | 0 Percent of participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas) | ORR by RECIST | 0 Percent of participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas) | ORR by RECIST | 0 Percent of participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas) | immune ORR by iRECIST | 0 Percent of participants |
Secondary
Antidrug Antibody (ADA) Occurrence
ADA were measured at Baseline and Post Baseline. Positive post baseline applies if at least one post-baseline value was positive.
Time frame: 24 months
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Positive | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Unknown | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Unknown | 0 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Positive | 1 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Negative | 2 Participants |
| WTX-330 Dose Escalation - 0.016 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Negative | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Unknown | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Unknown | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Positive | 0 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Negative | 3 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Negative | 2 Participants |
| WTX-330 Dose Escalation - 0.024 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Positive | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Positive | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Unknown | 0 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Negative | 4 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Negative | 2 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Unknown | 1 Participants |
| WTX-330 Dose Escalation - 0.032 mg/kg | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Positive | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Positive | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Negative | 3 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Unknown | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Negative | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Unknown | 2 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Indicated (Arm A) | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Positive | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Unknown | 4 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Negative | 8 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Positive | 1 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Antidrug Antibody (ADA) Occurrence | ADA at Baseline | Unknown | 0 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Negative | 5 Participants |
| WTX-330 Dose Expansion in Patients for Whom CPI Therapy is Not Indicated (Arm B) | Antidrug Antibody (ADA) Occurrence | ADA post Baseline | Positive | 0 Participants |
Secondary
Plasma Concentrations of IL-12 Cycle 1 - AUC
PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.
Time frame: 14 days
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of IL-12 Cycle 1 - AUC | 3221.5 day*pg/ml | Standard Deviation 1879.29 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of IL-12 Cycle 1 - AUC | 5144.7 day*pg/ml | Standard Deviation 3395.29 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of IL-12 Cycle 1 - AUC | 5986.4 day*pg/ml | Standard Deviation 2336.59 |
Secondary
Plasma Concentrations of IL-12 Cycle 1 - C Max
PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of IL-12 Cycle 1 - C Max | 1434.7 pg/ml | Standard Deviation 694.1 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of IL-12 Cycle 1 - C Max | 2298.0 pg/ml | Standard Deviation 1434.71 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of IL-12 Cycle 1 - C Max | 3022.0 pg/ml | Standard Deviation 787.48 |
Secondary
Plasma Concentrations of IL-12 Cycle 1 - Half Life
PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of IL-12 Cycle 1 - Half Life | 3.2138 day | Standard Deviation 1.33405 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of IL-12 Cycle 1 - Half Life | 3.2643 day | Standard Deviation 1.26642 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of IL-12 Cycle 1 - Half Life | 2.4809 day | Standard Deviation 0.75436 |
Secondary
Plasma Concentrations of IL-12 Cycle 1 - Time of Maximum Concentration Observation
PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of IL-12 Cycle 1 - Time of Maximum Concentration Observation | 4.90 h | Standard Deviation 1.473 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of IL-12 Cycle 1 - Time of Maximum Concentration Observation | 5.23 h | Standard Deviation 2.065 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of IL-12 Cycle 1 - Time of Maximum Concentration Observation | 6.48 h | Standard Deviation 2.182 |
Secondary
Plasma Concentrations of IL-12 Cycle 2 - AUC
PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.
Time frame: 14 days
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.~Overall Number of Participants Analyzed is lower for cycle 2, as not all participants continued on study and not all samples were available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of IL-12 Cycle 2 - AUC | 3569.4 day*pg/ml | Standard Deviation 636.45 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of IL-12 Cycle 2 - AUC | 1957.5 day*pg/ml | Standard Deviation 635.67 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of IL-12 Cycle 2 - AUC | 4349.9 day*pg/ml | Standard Deviation 1530.39 |
Secondary
Plasma Concentrations of IL-12 Cycle 2 - C Max
PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.~Overall Number of Participants Analyzed is lower for cycle 2, as not all participants continued on study and not all samples were available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of IL-12 Cycle 2 - C Max | 1331.5 pg/ml | Standard Deviation 26.16 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of IL-12 Cycle 2 - C Max | 2165.7 pg/ml | Standard Deviation 1933.23 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of IL-12 Cycle 2 - C Max | 3292.8 pg/ml | Standard Deviation 2236.7 |
Secondary
Plasma Concentrations of IL-12 Cycle 2 - Half Life
PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.~Overall Number of Participants Analyzed is lower for cycle 2, as not all participants continued on study and not all samples were available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of IL-12 Cycle 2 - Half Life | 2.2540 day | Standard Deviation 0.92905 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of IL-12 Cycle 2 - Half Life | 3.8541 day | Standard Deviation 0.92348 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of IL-12 Cycle 2 - Half Life | 2.7120 day | Standard Deviation 1.54085 |
Secondary
Plasma Concentrations of IL-12 Cycle 2 - Time of Maximum Concentration Observation
PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.~Overall Number of Participants Analyzed is lower for cycle 2, as not all participants continued on study and not all samples were available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of IL-12 Cycle 2 - Time of Maximum Concentration Observation | 13.80 h | Standard Deviation 13.435 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of IL-12 Cycle 2 - Time of Maximum Concentration Observation | 0.27 h | Standard Deviation 0.058 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of IL-12 Cycle 2 - Time of Maximum Concentration Observation | 2.95 h | Standard Deviation 1.782 |
Secondary
Plasma Concentrations of WTX-330 Cycle 1 - AUC
PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.
Time frame: 14 days
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of WTX-330 Cycle 1 - AUC | 0.7585 day*mcg/ml | Standard Deviation 0.50363 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of WTX-330 Cycle 1 - AUC | 1.1952 day*mcg/ml | Standard Deviation 0.84243 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of WTX-330 Cycle 1 - AUC | 1.7270 day*mcg/ml | Standard Deviation 0.75076 |
Secondary
Plasma Concentrations of WTX-330 Cycle 1 - C Max
PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of WTX-330 Cycle 1 - C Max | 0.2773 mcg/ml | Standard Deviation 0.11684 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of WTX-330 Cycle 1 - C Max | 0.4290 mcg/ml | Standard Deviation 0.29465 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of WTX-330 Cycle 1 - C Max | 0.8624 mcg/ml | Standard Deviation 0.17688 |
Secondary
Plasma Concentrations of WTX-330 Cycle 1 - Half Life
PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of WTX-330 Cycle 1 - Half Life | 2.1886 day | Standard Deviation 1.23394 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of WTX-330 Cycle 1 - Half Life | 2.7083 day | Standard Deviation 1.00754 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of WTX-330 Cycle 1 - Half Life | 3.3463 day | Standard Deviation 1.48342 |
Secondary
Plasma Concentrations of WTX-330 Cycle 1 - Time of Maximum Concentration Observation
PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 1
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of WTX-330 Cycle 1 - Time of Maximum Concentration Observation | 2.40 h | Standard Deviation 3.637 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of WTX-330 Cycle 1 - Time of Maximum Concentration Observation | 2.93 h | Standard Deviation 4.561 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of WTX-330 Cycle 1 - Time of Maximum Concentration Observation | 3.26 h | Standard Deviation 1.668 |
Secondary
Plasma Concentrations of WTX-330 Cycle 2 - AUC
PK described by Area Under Curve (0-14 day). Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose.
Time frame: 14 days
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.~Overall Number of Participants Analyzed is lower for cycle 2, as not all participants continued on study and not all samples were available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of WTX-330 Cycle 2 - AUC | 1.0247 day*mcg/ml | Standard Deviation 0.14275 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of WTX-330 Cycle 2 - AUC | 0.8744 day*mcg/ml | Standard Deviation 0.51499 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of WTX-330 Cycle 2 - AUC | 1.8042 day*mcg/ml | Standard Deviation 0.80145 |
Secondary
Plasma Concentrations of WTX-330 Cycle 2 - C Max
PK described by maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.~Overall Number of Participants Analyzed is lower for cycle 2, as not all participants continued on study and not all samples were available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of WTX-330 Cycle 2 - C Max | 0.3210 mcg/ml | Standard Deviation 0.0495 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of WTX-330 Cycle 2 - C Max | 0.6272 mcg/ml | Standard Deviation 0.60613 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of WTX-330 Cycle 2 - C Max | 1.0748 mcg/ml | Standard Deviation 0.70201 |
Secondary
Plasma Concentrations of WTX-330 Cycle 2 - Half Life
PK described by Half-Life Lambda z. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.~Overall Number of Participants Analyzed is lower for cycle 2, as not all participants continued on study and not all samples were available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of WTX-330 Cycle 2 - Half Life | 3.3296 day | Standard Deviation 0.34454 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of WTX-330 Cycle 2 - Half Life | 2.8809 day | Standard Deviation 1.7391 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of WTX-330 Cycle 2 - Half Life | 4.0216 day | Standard Deviation 1.06686 |
Secondary
Plasma Concentrations of WTX-330 Cycle 2 - Time of Maximum Concentration Observation
PK described by time to maximum concentration. Sample collection timepoints: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Time frame: 0, 4, 8, 24, 48, and 168 hours post-dose on Day 1 of Cycle 2
Population: Comprehensive PK was only assessed for the dose-escalation arms. Therefore, only the 3 dose-escalation arms are represented in these analyses, and not the two expansion arms.~Overall Number of Participants Analyzed is lower for cycle 2, as not all participants continued on study and not all samples were available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| WTX-330 Dose Escalation - 0.016 mg/kg | Plasma Concentrations of WTX-330 Cycle 2 - Time of Maximum Concentration Observation | 0.30 h | Standard Deviation 0 |
| WTX-330 Dose Escalation - 0.024 mg/kg | Plasma Concentrations of WTX-330 Cycle 2 - Time of Maximum Concentration Observation | 1.40 h | Standard Deviation 1.992 |
| WTX-330 Dose Escalation - 0.032 mg/kg | Plasma Concentrations of WTX-330 Cycle 2 - Time of Maximum Concentration Observation | 2.15 h | Standard Deviation 2.136 |